NCLT Initiates CIRP Against Shilpa Medicare Subsidiary FTF Pharma Over ₹2.18 Crore Dues
Shilpa Medicare Ltd · Others (Uncategorized) · 10 Sept 2026, 8:29 pm
NCLT Initiates CIRP Against Shilpa Medicare Subsidiary FTF Pharma Over ₹2.18 Crore Dues NCLT Ahmedabad Bench admitted a Section 9 IBC petition filed by Immacule Lifesciences against FTF Pharma, a wholly owned subsidiary of Shilpa Medicare, ordering Corporate Insolvency Resolution Process (CIRP) commencement on 9th Sep'26. The proceedings involve an outstanding operational debt of ₹2.18 Cr under a technology transfer agreement. NCLT imposed a statutory moratorium and appointed Sunil Kumar Kedia as Interim Resolution Professional. Shilpa Medicare stated no contravention was found against the listed entity, financial impact remains presently unascertainable, and it is consulting legal advisors.
Original exchange filing (PDF)
More announcements from Shilpa Medicare Ltd
- Q2FY27 Earnings Conference Call 05 November 2026 · 11 Nov 2026
- Audio link of the Investor Conference call for the quarter ended 30 September 2026. · 06 Nov 2026
- Update on Corporate Insolvency Resolution Process of FTF Pharma Private Limited, a Wholly Owned Subsidiary of Shilpa Medicare Limited · 05 Nov 2026
- Investor Presentation for the Quarter and Half year ended 30 September 2026 · 05 Nov 2026
- Outcome of the Board Meeting · 05 Nov 2026
- Shilpa Medicare Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 05 Nov 2026
- Financial Results for the Quarter and Half year ended 30 September 2026 · 05 Nov 2026
- SHILPA MEDICARE LIMITED has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . · 05 Nov 2026
